Concert Pharmaceuticals is a clinical stage biopharmaceutical company applying its knowledge of deuterium chemistry to discover and develop novel small molecule drugs. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. The Company's approach typically starts with approved drugs that may be improved with deuterium substitution. Concert Pharmaceuticals's technology provides the opportunity to develop products that may compete with the non-deuterated drug in existing markets or to leverage the known activity of approved drugs to expand into new indications. The Company's deuterated chemical entity platform, or DCE Platform, has broad potential across numerous therapeutic areas.

Employee Rating

2.9More
TypePublic
HQLexington, US
Founded2006
Size (employees)64 (est)-7%
Websiteconcertpharma.com
Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Concert Pharmaceuticals

Roger Tung

Roger Tung

Founder, President, CEO & Board of Directors
Nancy Stuart

Nancy Stuart

COO
Lynette Herscha

Lynette Herscha

General Counsel
James Cassella

James Cassella

Chief Development Officer
Show more

Concert Pharmaceuticals Office Locations

Concert Pharmaceuticals has an office in Lexington
Lexington, (HQ)
500 99 Hayden Ave
Show all (1)
Report incorrect company information

Concert Pharmaceuticals Financials and Metrics

Concert Pharmaceuticals Revenue

Concert Pharmaceuticals's revenue was reported to be $143.89 m in FY, 2017
USD

Revenue (Q3, 2018)

11.0k

Net income (Q3, 2018)

(17.4m)

EBIT (Q3, 2018)

(17.3m)

Market capitalization (4-Dec-2018)

295.7m

Closing stock price (4-Dec-2018)

12.6

Cash (30-Sep-2018)

39.6m
Concert Pharmaceuticals's current market capitalization is $295.7 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

66.7m174.0k143.9m

General and administrative expense

13.1m14.4m21.0m

R&D expense

28.9m37.0m30.2m

Operating expense total

41.9m51.3m51.2m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.6m1.2m4.4m53.4m1.7m56.0k71.0k26.0k20.0k15.0k143.8m11.0k

General and administrative expense

2.5m2.7m3.5m3.3m3.3m3.6m3.8m3.4m5.3m5.7m4.9m5.6m5.5m6.3m

R&D expense

5.6m6.2m8.6m8.4m7.1m10.5m9.8m8.1m8.2m7.3m7.1m8.7m8.9m11.0m

Operating expense total

8.1m9.0m12.0m11.7m10.4m14.0m13.6m11.5m13.5m13.0m12.0m14.3m14.4m17.4m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

92.5m40.6m27.7m

Accounts Receivable

70.0k27.0k155.0k

Current Assets

144.1m97.7m205.7m

PP&E

2.3m2.2m2.2m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

24.2m(50.7m)95.6m

Depreciation and Amortization

785.0k893.0k1.0m

Accounts Payable

(90.0k)44.0k113.0k

Cash From Operating Activities

23.1m(45.3m)102.9m
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Concert Pharmaceuticals News and Updates

Report incorrect company information

Concert Pharmaceuticals Blogs

Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata

Company On Track to Report Topline Data from the 4 mg and 8 mg Twice-Daily Cohorts in Fourth Quarter of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Sep. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will include an additional cohort of patients in the Phase 2a trial

Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Company Update

-- Clinical Programs Advance with CTP-543 Phase 2a Topline Data in Alopecia Areata and CTP-692 Phase 1 Trial Initiation Expected in the Fourth Quarter of 2018 -- -- Conference Call Scheduled Today at 8:30 A.M. EDT -- LEXINGTON, Mass. --(BUSINESS WIRE)--Aug. 2, 2018-- Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018

LEXINGTON, Mass. --(BUSINESS WIRE)--Jul. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2018 financial results on Thursday, August 2, 2018 , before the U.S. financial markets open. The Company will host a conference call and webcast at

Concert Pharmaceuticals Company Life and Culture

Report incorrect company information

Concert Pharmaceuticals Frequently Asked Questions

  • When was Concert Pharmaceuticals founded?

    Concert Pharmaceuticals was founded in 2006.

  • Who are Concert Pharmaceuticals key executives?

    Concert Pharmaceuticals's key executives are Roger Tung, Nancy Stuart and Lynette Herscha.

  • How many employees does Concert Pharmaceuticals have?

    Concert Pharmaceuticals has 64 employees.

  • What is Concert Pharmaceuticals revenue?

    Latest Concert Pharmaceuticals annual revenue is $143.9 m.

  • What is Concert Pharmaceuticals revenue per employee?

    Latest Concert Pharmaceuticals revenue per employee is $2.2 m.

  • Who are Concert Pharmaceuticals competitors?

    Competitors of Concert Pharmaceuticals include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is Concert Pharmaceuticals headquarters?

    Concert Pharmaceuticals headquarters is located at 500 99 Hayden Ave, Lexington.

  • Where are Concert Pharmaceuticals offices?

    Concert Pharmaceuticals has an office in Lexington.

  • How many offices does Concert Pharmaceuticals have?

    Concert Pharmaceuticals has 1 office.